5HT antagonists attenuate MK801-impaired radial arm maze performance in rats

Neurobiology of Learning and Memory

Volumn 71, Issue 3, 1999, Pages 259-271

  Boast, Carl ^a   Bartolomeo, Adam C ^a   Morris, Herman ^a   Moyer, John A ^a  

^a PFIZER INC   (United States)

Author keywords

Alzheimer's disease; Arecoline; Buspirone; Delayed nonmatch to sample; Dementia; Dizocilpine; Glutamate; Ondansetron; Ritanserin; WAY 100635

Indexed keywords

ARECOLINE; BUSPIRONE; DIZOCILPINE; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ONDANSETRON; RITANSERIN; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 2 ANTAGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN ANTAGONIST;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MAZE TEST; NONHUMAN; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TASK PERFORMANCE;

EID: 0032817311     PISSN: 10747427     EISSN: None     Source Type: Journal    
DOI: 10.1006/nlme.1998.3886     Document Type: Article

References (45)

1. Aigner T. G. Pharmacology of memory: Cholinergic-glutamatergic interactions. Current Opinion in Neurobiology. 5:1995;155-160.
2. Altman H. J., Normile H. J. What is the nature of the role of the serotonergic nervous system in learning and memory: Prospects for development of an effective treatment strategy for senile dementia. Neurobiology of Aging. 9:1988;627-638.
3. Azmitia E. C., Segal M. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. Journal of Comparative Neurology. 179:1978;641-668.
4. Bartolomeo A. C., Morris H., Boast C. A. Arecoline via mini-osmotic pump improves AF64A-impaired radial maze performance in rats: A possible model of Alzheimer's disease. Neurobiology of Learning and Memory. 68:1997;333-342.
5. Beck S. G., Choi K. C., List T. J. Comparison of 5-hydroxytryptamine 1A-mediated hyperpolarization in CA1 and CA3 hippocampal pyramidal cells. Journal of Pharmacology and Experimental Therapeutics. 263:1992;350-359.
6. Bowen D. M., Francis P. T., Pangalos M. N., Stephens P. H., Procter A. W. Treatment strategies for Alzheimer's disease. Lancet. 339:1992;132-133.
7. Braak H., Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathologica. 82:1991;239-259.
8. Butelman E. R. The effect of NMDA antagonists in the radial arm maze with interposed delay. Pharmacology, Biochemistry and Behavior. 35:1990;533-536.
9. 3. British Journal of Pharmacology. 94:1988;397-412.
10. 1A. Brain Research. 595:1992;50-56.
11. 1A. British Journal of Pharmacology. 105:1992;720-726.
12. Collingridge G. L., Singer W. Excitatory amino acid receptors and synaptic plasticity. Trends in Pharmacological Sciences. 11:1990;290-296.
13. Cowburn R. F., Hardy J. A., Roberts P. J. Glutamatergic neurotransmission in Alzheimer's disease. Biochemical Society Transactions. 18:1990;390-392.
14. Danysz W., Wroblewski J. T., Costa E. Learning impairment in rats byNd. Neuropharmacology. 27:1988;653-656.
15. 1A. Behavioral Brain Research. 73:1996;337-353.
16. Francis P. T., Sims N. R., Procter A. W., Bowen D. M. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: Investigative and therapeutic perspectives. Journal of Neurochemistry. 60:1993;1589-1604.
17. Freund T. F., Gulyas A. I., Acsady L., Gorcs T., Toth K. Serotonergic control of the hippocampus via local inhibitory interneurons. Proceedings of the National Academy of Sciences of the United States of America. 87:1990;8501-8505.
18. Greenamyre J. T., Young A. B. Excitatory amino acids and Alzheimer's disease. Neurobiology of Aging. 10:1989;593-602.
19. 1A. Psychopharmacology. 127:1996;245-254.
20. Hargreaves E. L., Cain D. P. Hyperactivity, hyper-reactivity, and sensorimotor deficits induced by low doses of theNd. Behavioural Brain Research. 47:1992;23-33.
21. Hyman B. T., Van Hoesen G. V., Damasio A. R. Alzheimer's disease: Glutamate depletion in the hippocampal perforant pathway zone. Annals of Neurology. 22:1987;37-40.
22. Jacobs B. L., Azmitia E. C. Structure and function of the brain serotonin system. Physiological Reviews. 72:1992;165-229.
23. Jansen K. L., Faull R. L., Dragunow M., Synek B. L. Alzheimer's disease: Changes in hippocampalNd. Neuroscience. 39:1990;613-627.
24. Jones R. S. G. Entorhinal-hippocampal connections: A speculative view of their function. Trends in Neuroscience. 16:1993;58-64.
25. Leysen J. E., Gommeren W., Van Gompel P., Wynants J., Janssen P. F., Laduron P. M. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. Molecular Pharmacology. 27:1985;600-611.
26. Markham H., Segal M. Acetylcholine potentiates responses toNd. Neuroscience Letters. 113:1990;62-65.
27. 1A. Brain Research. 728:1996;175-180.
28. Maurer S. A., Storch F. E., LaForge R. R., Boast C. A. Task difficulty determines the differential memory-impairing effects of EAA antagonists in gerbils. Pharmacology, Biochemistry and Behavior. 51:1995;345-351.
29. McEntee W. J., Crook T. H. Serotonin, memory and the aging brain. Psychopharmacology. 103:1991;143-149.
30. Morris R. G. M., Anderson E., Lynch G. S., Baudry M. Selective impairment of learning and blockade of long-term potentiation by anNd. Nature. 319:1986;774-776.
31. Myhrer T. Animal models of Alzheimer's disease: Glutamatergic denervation as an alternative approach to cholinergic denervation. Neuroscience and Biological Reviews. 17:1993;195-202.
32. Olton D. S. The use of animal models to evaluate the effects of neurotoxins on cognitive processes. Neurobehavioral Toxicology and Teratology. 5:1983;635-640.
33. Palmer A. M., Gershon S. Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic. FASEB Journal. 4:1990;2745-2752.
34. Pitkanen M., Sirvio J., MacDonald E., Niemi S., Ekonsalo T., Riekkinen P. Sr. The effects ofd. European Neuropsychopharmacology. 5:1995;457-463.
35. Procter A. W., Palmer A. M., Francis P. T., Lowe S. L., Neary D., Murphy E., Doshi R., Bowen D. M. Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer's disease. Journal of Neurochemistry. 50:1988;790-802.
36. Riblet L. A., Taylor D. P., Eison M. S., Stanton H. C. Pharmacology and neurochemistry of buspirone. Journal of Clinical Psychiatry. 43:1982;11-18.
37. Richards M. H. Relative potencies of agonists and differential sensitivity toN. Journal of Pharmacology and Experimental Therapeutics. 255:1990;83-89.
38. Schmitz D., Empson R. M., Gloveli T., Heinemann U. Serotonin reduces synaptic excitation of principal cells in the superficial layers of rat hippocampal-entorhinal cortex combined slices. Neuroscience Letters. 190:1995;37-40.
39. Shapiro M. L., Caramanos Z. NMDA antagonist MK-801 impairs acquisition but not performance of spatial working and reference memory. Psychobiology. 18:1990;231-243.
40. Shetty H. U., Daly E. M., Grieg N. H., Rapoport S. I., Soncrant T. T. An automatic reaction control chemical ionization technique in ion trap detector for quantitative plasma profiling of arecoline in treated Alzheimer patients. Journal of the American Society for Mass Spectrometry. 2:1991;168-173.
41. 3. Journal of Neuroscience. 15:1995;2445-2452.
42. Steward O., Loesche J., Horton W. C. Behavioral correlates of denervation and reinnervation of the hippocampal formation of the rat: Open field activity and cue utilization following bilateral entorhinal cortex lesions. Brain Research Bulletin. 2:1977;41-48.
43. Ward L., Mason S. E., Abraham W. C. Effects of the NMDA antagonists CPP and MK-801 on radial arm maze performance in rats. Pharmacology, Biochemistry and Behavior. 35:1990;785-790.
44. Wong E. H. F., Kemp J. A., Priestley T., Knight A. R., Woodruff G. N., Iversen L. L. The anticonvulsant MK-801 is a potentNd. Proceedings of the National Academy of Sciences of the United States of America. 83:1986;7104-7108.
45. Wozniak D. F., Olney J. W., Kettinger L., Price M., Miller J. P. Behavioral effects of MK-801 in the rat. Psychopharmacology. 101:1990;47-56.